Bordeaux (France) – December 1, 2009 - Fluofarma, a leading company in High Content Screening (HCS) technologies, which offers services and counseling to the Pharmaceutical industry, announced today the publication in the international scientific journal “Analytical Chemistry”, of the original article “Recombinant differential anchorage probes that tower over the spatial dimension of intracellular signals for high content screening and analysis”.
“This scientific publication represents a major step for Fluofarma” says Jean-Baptiste Pin, CEO of Fluofarma. He added: “This work done in collaboration with prestigious academic centers in France (INSERM, Institut Bergonié, Hôpital du Haut Lévêque) and Italy (Università di Padova) shows indeed applications of Fluofarma technology in basic research, high content multiplexed library screening, compound characterization, and drug profiling”.
In short the authors describe novel strategy based on fluorescent probes capable to encode the spatial dimension of intracellular signals into “all-or-none” fluorescence intensity changes. The resulting signals can be acquired in single cells at high throughput by automated flow cytometry, (i) bypassing image acquisition and analysis, (ii) providing a direct quantitative readout, and (iii) allowing the exploration of large experimental series.
These results show a new high content analytical strategy industrialized by Fluofarma and capable to capture molecular effects at the single cell level on large cellular populations and thus, to obtain a precise determination of quantitative parameters characterizing test conditions or compounds.
An electronic version of the paper can be accessed on line via the
Analytical Chemistry website at: http://pubs.acs.org/doi/full/10.1021/ac9015227
About Fluofarma : Fluofarma is a privately-held contract service provider which offers High Content Screening (HCS) services and technologies for target and drug discovery, predictive toxicity testing. The company was created in 2003 by a team of scientists with in-depth, expertise in oncology, neurobiology and chemistry.
Since its inception, Fluofarma has developed innovative technologies designed for automated flow cytometry, confocal microscopy and laser scanning cytometry to improve the level of understanding of compounds and their effects, from the earliest stage of the discovery process onwards.
Fluofarma’ services include:
- Development & miniaturization of cell-based assays,
- Functional screening for target and drug discovery,
- Compound profiling and mechanism of action studies,
- Predictive toxicity testing at a large scale.
The company is headquartered in Bordeaux, France, and now works with over 30 major pharmaceutical and biotechnology companies worldwide. For more information, please visit: http://www.fluofarma.com
